C4 Therapeutics has dosed the first patient in MOMENTUM, a Phase 2 study of the IKZF1/3 molecular glue degrader cemsidomide plus dexamethasone in fourth-line or later multiple myeloma, deliberately structured as a potential accelerated approval pathway. The company also plans to open a Phase 1b study in the second quarter of 2026 combining cemsidomide with elranatamab, a BCMA-directed bispecific, to test earlier-line utility. Alongside these clinical moves, C4 closed 2025 with $297.1 million in cash and securities, guiding runway through the end of 2028, reported full-year revenue of $35.9 million, R&D spend of $104.2 million, and a net loss of $105.0 million. A second partnered degrader with Biogen, the BTK candidate BIIB145 for autoimmune disease, has also entered the clinic, reinforcing external demand for the platform.
The strategic question is whether cemsidomide can carve out a defensible position in a myeloma market reshaped by bispecifics, CAR-Ts, and next-generation cereblon modulators. The Phase 2 design targets a post–T-cell engager and post–CAR-T population where options remain thin, a setting where a potent oral degrader could be clinically and commercially attractive. Yet the bar has risen: single‑arm response‑rate packages in hematologic malignancies now face tighter regulatory and payer scrutiny, and competitors are racing to anchor combination regimens that could define standard sequences before new entrants arrive.
For patients, the near-term relevance is twofold. First, MOMENTUM aims at a population increasingly seen in practice as BCMA and GPRC5D agents move earlier. Demonstrating durable responses after these modalities would directly address a growing care gap. Second, the planned bispecific combination tests whether targeted protein degradation can amplify T-cell–mediated killing without compounding infection risk and cytopenias that already constrain real-world use. Hematologists will look for clear guidance on sequencing, steroid management, and safety mitigation, all of which will hinge on high-quality clinical and real-world evidence to support uptake.
Payers will press for differentiation beyond legacy IMiDs now eroding with generics and beyond the next wave of CELMoDs that are setting efficacy and safety expectations. An accelerated approval case in late lines may not translate into broad coverage without data that speak to resource use, infection-related hospitalizations, and the ability to enable less intensive dosing of costly immunotherapies. Early health economics planning, pragmatic trial elements, and post-market evidence commitments will be essential to secure favorable positioning on formularies already crowded with high-cost combinations.
For competitors, the move signals that degrader chemistry is no longer confined to discovery narratives. The combination with elranatamab foreshadows a broader trend: targeted degraders co-deployed as immunomodulatory backbones rather than stand‑alone salvage agents. The Biogen BTK degrader entering the clinic underscores a second industry pivot—translating degradation to immunology and, potentially, neuroinflammation—where large-cap partners are seeking differentiated mechanisms that can navigate class safety baggage while offering oral convenience.
C4’s portfolio breadth adds optionality. The EGFR L858R degrader program, informed by China-based dose-escalation data from Betta Pharmaceuticals, hints at a cross-border development model that can compress timelines and de-risk early decisions before global moves. Combined with a multiyear cash runway secured through equity and partnerships, the company has the operational space to run confirmatory strategies in parallel rather than in series, a practical edge in a fast-moving landscape.
The next 18–24 months will determine trajectory: updated cemsidomide analyses, first combination signals, and clarity on regulatory receptivity to a single-arm late-line package. The competitive race is now about more than response rates. Can C4 generate practice-changing evidence and a payer-ready value story quickly enough to secure class leadership before CELMoD-driven combinations and bispecific sequencing harden into default pathways?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
